NCT06244862View on ClinicalTrials.gov

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

August 8, 2025

Study Completion Date

February 1, 2026

Conditions

Hemophagocytic Syndromes

Interventions

DRUG

Ruxolitinib

Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER